ST. PAUL, Minn., Nov 29, 2011 (BUSINESS WIRE) — St. Jude Medical, Inc. STJ +6.19% , a global medical device company, today announced it has received U.S. Food and Drug Administration (FDA) approval of its Unify Quadra(R) cardiac resynchronization therapy defibrillator (CRT-D) and Quartet(R) Left Ventricular Quadripolar Pacing Lead. The company will begin shipping the products to its sales force to begin providing to customers immediately.
As the industry’s first quadripolar pacing system, the Unify Quadra CRT-D and Quartet lead offer physicians the ability to effectively and efficiently manage the ever-changing needs of patients with heart failure. The system integrates multiple pacing configurations and TailoredTherapy(TM) features that enable physicians to optimize the system at implant and follow-up, as well as better manage common pacing complications without having to surgically reposition the lead. The system is also approved for remote patient management utilizing the Merlin.net(R) Patient Care Network.